TSE:TH Theratechnologies (TH) Stock Price, News & Analysis → My next big prediction isn’t a prediction (From Porter & Company) (Ad) Free TH Stock Alerts C$1.66 -0.03 (-1.78%) (As of 03/18/2024 ET) Add Compare Share Share Today's RangeC$1.65▼C$1.7250-Day RangeC$1.64▼C$3.0552-Week RangeC$1.22▼C$5.84Volume34,271 shsAverage Volume45,802 shsMarket CapitalizationC$76.33 millionP/E RatioN/ADividend Yield3.76%Price TargetC$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Theratechnologies alerts: Email Address Theratechnologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside231.3% UpsideC$5.50 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 stars 3.3 Analyst's Opinion Consensus RatingTheratechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$5.50, Theratechnologies has a forecasted upside of 231.3% from its current price of C$1.66.Amount of Analyst CoverageTheratechnologies has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for TH. Previous Next 1.7 Dividend Strength Dividend LeadershipTheratechnologies is a leading dividend payer. It pays a dividend yield of 3.76%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthTheratechnologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TH. Previous Next 1.4 News and Social Media Coverage News SentimentTheratechnologies has a news sentiment score of -0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.Search Interest1 people have searched for TH on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theratechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.29% of the stock of Theratechnologies is held by insiders.Percentage Held by Institutions50.88% of the stock of Theratechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Theratechnologies is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theratechnologies is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Theratechnologies, their PEG ratio cannot be calculated. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Theratechnologies Stock (TSE:TH)Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Read More TH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TH Stock News HeadlinesMarch 11, 2024 | msn.comNurse-Led Strategy Reduces Cardiovascular Risk Factors for People With HIVFebruary 27, 2024 | morningstar.comTheratechnologies Shares Sink Premarket After FDA Refusal to File LetterMarch 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. February 27, 2024 | seekingalpha.comTheratechnologies stock plunges after FDA denies review of Trogarzo sBLAFebruary 23, 2024 | finance.yahoo.comTheratechnologies Full Year 2023 Earnings: Misses ExpectationsFebruary 21, 2024 | finance.yahoo.comTheratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 GuidanceFebruary 21, 2024 | markets.businessinsider.comHere's what Wall Street expects from Theratechnologies's earnings reportFebruary 20, 2024 | benzinga.com7THTX : Theratechnologies Earnings PreviewMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.February 20, 2024 | finance.yahoo.comTheratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of ActionFebruary 6, 2024 | finance.yahoo.comTheratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateJanuary 31, 2024 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Theratechnologies StockJanuary 25, 2024 | msn.comFDA denies approval for Theratechnologies’ tesamorelin F8January 24, 2024 | marketwatch.comTheratechnologies: FDA Rejects Newer Egrifta FormulationJanuary 24, 2024 | marketwatch.comTheratechnologies Shares Slide Premarket as FDA Turns Away Newer EgriftaJanuary 24, 2024 | markets.businessinsider.comTheratechnologies Stock Falls On CRL From FDA For F8 Formulation Of TesamorelinJanuary 24, 2024 | marketwatch.comTheratechnologies Shares Sink at Open After FDA Rejects Newer Tesamorelin FormulationJanuary 24, 2024 | finance.yahoo.comTheratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLAJanuary 23, 2024 | marketwatch.comTheratechnologies Shares Fall as FDA Continues to Review License Application for TesamorelinJanuary 23, 2024 | msn.comTheratechnologies stock slides as Egrifta review runs beyond FDA target dateJanuary 23, 2024 | markets.businessinsider.comTheratechnologies Says FDA Needs More Time To Decide On Tesamorelin F8 SBLAJanuary 2, 2024 | finanznachrichten.deTheratechnologies Submits sBLA for Trogarzo Intramuscular (IM) Method of Administration to FDADecember 19, 2023 | entrepreneur.com3 Biotech Stock Buys to Boost and Supercharge PortfoliosDecember 18, 2023 | theglobeandmail.comClosing Bell: Theratechnologies flat on Monday (TH)December 13, 2023 | msn.comTheratechnologies announces FDA nod of Trogarzo 90-second intravenous push loading doseNovember 24, 2023 | finance.yahoo.comTheratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation AwardNovember 2, 2023 | msn.comTheratechnologies (THTX) Price Target Increased by 16.41% to 5.54See More Headlines Receive TH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/18/2024Next Earnings (Estimated)4/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:TH CUSIPN/A CIKN/A Webwww.theratech.com Phone+1-514-3367800FaxN/AEmployees103Year FoundedN/APrice Target and Rating Average Stock Price TargetC$5.50 High Stock Price TargetC$5.50 Low Stock Price TargetC$5.50 Potential Upside/Downside+223.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($1.23) Trailing P/E RatioN/A Forward P/E Ratio55.58 P/E Growth-8.5Net IncomeC$-23,960,000.00 Net Margins-29.30% Pretax MarginN/A Return on Equity-1,116.86% Return on Assets-6.33% Debt Debt-to-Equity Ratio562.07 Current Ratio1.34 Quick Ratio0.64 Sales & Book Value Annual SalesC$81.76 million Price / Sales0.96 Cash FlowC$0.45 per share Price / Cash Flow3.76 Book ValueC($0.45) per share Price / Book-3.78Miscellaneous Outstanding Shares45,980,000Free FloatN/AMarket CapC$78.17 million OptionableNot Optionable Beta1.73 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Paul Lévesque (Age 59)President, CEO & Director Comp: $1.6MMr. Philippe Dubuc M.B.A. (Age 57)MBA, Senior VP & CFO Comp: $585.32kMr. Jocelyn Lafond L.L.M. (Age 56)LL.B., General Counsel & Corporate Secretary Comp: $428.24kDr. Christian Marsolais Ph.D. (Age 61)Senior VP & Chief Medical Officer Comp: $588.42kMr. John Leasure (Age 59)Global Commercial Officer Comp: $569.88kHon. Andre Dupras M.Sc. (Age 60)Vice President of Human Resources More ExecutivesKey CompetitorsPediapharmCVE:PDPMedicenna TherapeuticsTSE:MDNABriaCell TherapeuticsTSE:BCTIntelGenx TechnologiesCVE:IGXEmerald Health TherapeuticsCVE:EMHView All CompetitorsInsidersDale WeilBought 36,200 shares on 11/1/2023Total: C$49,956.00 ($1.38/share)Joseph ArenaBought 10,000 shares on 10/30/2023Total: C$9,250.00 ($0.93/share)Dawn SvoronosBought 15,800 shares on 10/27/2023Total: C$21,646.00 ($1.37/share)Philippe DubucBought 8,000 shares on 10/27/2023Total: C$10,855.20 ($1.36/share)View All Insider Transactions TH Stock Analysis - Frequently Asked Questions Should I buy or sell Theratechnologies stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TH shares. View TH analyst ratings or view top-rated stocks. What is Theratechnologies' stock price target for 2024? 2 Wall Street analysts have issued 12-month price objectives for Theratechnologies' shares. Their TH share price targets range from C$5.50 to C$5.50. On average, they expect the company's share price to reach C$5.50 in the next year. This suggests a possible upside of 231.3% from the stock's current price. View analysts price targets for TH or view top-rated stocks among Wall Street analysts. How have TH shares performed in 2024? Theratechnologies' stock was trading at C$2.14 on January 1st, 2024. Since then, TH stock has decreased by 22.4% and is now trading at C$1.66. View the best growth stocks for 2024 here. When is Theratechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 10th 2024. View our TH earnings forecast. How were Theratechnologies' earnings last quarter? Theratechnologies Inc. (TSE:TH) announced its quarterly earnings results on Wednesday, February, 21st. The company reported ($0.11) earnings per share (EPS) for the quarter. The business earned $31.93 million during the quarter. Theratechnologies had a negative trailing twelve-month return on equity of 1,116.86% and a negative net margin of 29.30%. What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), BCE (BCE), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), Nemaska Lithium (NMX), Shopify (SHOP), United Therapeutics (UTHR) and Avigilon (AVO). How do I buy shares of Theratechnologies? Shares of TH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:TH) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.